MOTS-c and Imaging Contrast Dye: What You Need to Know Before Your Scan

What MOTS-c Is and How It Works

MOTS-c is a 16-amino-acid peptide encoded in the mitochondrial 12S ribosomal RNA gene. It was first isolated and characterized by Lee et al. In a 2015 Cell Metabolism paper that demonstrated its role in regulating glucose metabolism through AMPK activation and fatty acid oxidation [1]. Subcutaneous doses used in human experimental contexts typically range from 5 mg to 10 mg, though no FDA-approved indication exists as of this writing [2].

Mechanism at the Cellular Level

MOTS-c translocates from mitochondria to the nucleus under metabolic stress, where it modifies transcription of genes involved in the folate and methionine cycles [1]. AMPK activation by MOTS-c suppresses de novo lipogenesis and increases glucose uptake in skeletal muscle. These effects overlap with the mechanisms of metformin, a point relevant to kidney safety discussions below.

Current Regulatory Status

The FDA has not approved MOTS-c for any indication [2]. It is compounded and used off-label in longevity and metabolic optimization contexts. Because it sits outside the FDA approval framework, there is no manufacturer-supplied prescribing information with a formal drug interaction section. That absence of a label does not mean absence of risk.

Pharmacokinetics Relevant to Imaging

Published rodent data from Lee et al. (2015) and follow-up work by Kim et al. (2018) in Aging suggest rapid systemic distribution after injection, with a plasma half-life estimated at roughly 30 minutes [1, 3]. This short half-life means that by the time a contrast scan begins, most of the peptide is cleared. Even so, downstream AMPK-mediated effects on renal tubular cells may persist longer than the peptide itself.

Iodinated Contrast and Kidney Function

Iodinated contrast agents used in CT scans, including iohexol (Omnipaque) and iodixanol (Visipaque), are filtered exclusively by glomerular filtration and can precipitate contrast-induced acute kidney injury (CI-AKI) in susceptible patients [4].

Incidence and Risk Thresholds

The American College of Radiology (ACR) Manual on Contrast Media (2023 edition) states that CI-AKI risk rises substantially when baseline eGFR falls below 30 mL/min/1.73 m² [4]. A 2020 meta-analysis in JAMA Internal Medicine (Aycock et al., N = 107,335 patients across 28 studies) found an overall CI-AKI incidence of 6.4% in high-risk inpatient populations, compared with 0.6% in outpatients with normal renal function [5].

Why MOTS-c Adds Complexity

MOTS-c activates AMPK in renal proximal tubular cells [1]. AMPK activation in these cells has been shown in animal models to be protective against ischemic injury, but the same pathway can theoretically blunt the vasodilatory compensation that protects the kidney during contrast osmotic stress [6]. No human trial has tested this specific combination. The concern is mechanistic, not empirical.

eGFR Testing Before Your Scan

Any patient using MOTS-c who is scheduled for contrast-enhanced CT should have a current serum creatinine and calculated eGFR obtained within 30 days of the scan, per ACR guidance [4]. If eGFR is <30 mL/min/1.73 m², the radiologist and ordering physician should jointly decide whether to proceed, use iso-osmolar contrast, or switch to a non-contrast protocol.

Gadolinium-Based Contrast and MRI

Gadolinium-based contrast agents (GBCAs) such as gadobutrol (Gadavist) and gadoterate meglumine (Dotarem) are used in MRI. They carry a distinct risk profile from iodinated agents.

Nephrogenic Systemic Fibrosis

The FDA issued a black box warning for GBCAs in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²) due to the risk of nephrogenic systemic fibrosis (NSF), a rare but serious fibrosing condition [2]. Linear GBCAs carry higher NSF risk than macrocyclic agents. The ACR recommends macrocyclic agents when gadolinium is deemed necessary in patients with reduced kidney function [4].

Gadolinium Retention

A separate concern, not linked to NSF, is gadolinium deposition in brain tissue. The FDA Safety Communication (2017) notes that gadolinium retention has been observed across all GBCA classes, though clinical significance in patients with normal renal function remains under study [2]. MOTS-c has no known effect on gadolinium clearance, but prescribers should document the combination and monitor for unexpected neurological symptoms.

Practical Guidance for MRI

Patients using MOTS-c do not need to hold the peptide before MRI solely because of GBCA exposure, given the lack of direct interaction data. The kidney function threshold (eGFR <30 mL/min/1.73 m²) remains the operative decision point, as it is for any patient.

The AMPK-Metformin Parallel: A Relevant Comparison

Metformin, the most prescribed oral antidiabetic globally, is also an AMPK activator. Guidelines from the American College of Radiology and the European Society of Urogenital Radiology have historically recommended holding metformin 48 hours before iodinated contrast in patients with eGFR <45 mL/min/1.73 m², primarily to prevent lactic acidosis in the event of contrast-induced AKI [4, 7].

The reasoning goes like this: if the kidney sustains contrast-mediated injury, metformin accumulates, and elevated metformin concentrations increase the risk of metformin-associated lactic acidosis (MALA). Because MOTS-c activates the same AMPK pathway through a different molecular route, an analogous precautionary hold may be worth discussing with your physician, even though no guideline currently recommends it explicitly for MOTS-c.

Does MOTS-c Cause Lactic Acidosis?

Available preclinical data do not suggest MOTS-c produces lactic acidosis directly. Unlike metformin, MOTS-c does not inhibit mitochondrial complex I, which is the mechanism behind metformin-associated lactate accumulation [1, 8]. This distinction matters. The AMPK activation is shared, but the upstream mechanism is different, and the lactic acidosis concern does not transfer automatically.

A Framework for Clinical Decision-Making

The following stepwise approach reflects a reasonable precautionary standard, pending direct clinical evidence:

1. Obtain eGFR within 30 days of any planned contrast scan.
2. If eGFR is ≥45 mL/min/1.73 m², no MOTS-c hold is likely needed based on current mechanistic reasoning.
3. If eGFR is 30 to 44 mL/min/1.73 m², discuss elective hold of MOTS-c for 24 to 48 hours before and after contrast exposure with your prescribing physician.
4. If eGFR is <30 mL/min/1.73 m², contrast imaging should be reconsidered regardless of MOTS-c use.
5. Ensure post-procedure hydration with 1 to 1.5 mL/kg/hour of isotonic saline for 6 hours, per ACR hydration protocols [4].

Hydration, Alcohol, and Contrast Safety

Pre-procedure hydration is one of the most evidence-supported interventions for preventing CI-AKI. A 2019 Cochrane review (Zoungas et al. Update, 8 RCTs, N = 1,220) found that intravenous isotonic saline reduced CI-AKI incidence compared with no hydration (relative risk 0.52, 95% CI 0.29 to 0.93) [9].

Can I Drink Alcohol on MOTS-c?

No controlled trial has studied alcohol consumption in the context of MOTS-c use specifically. Alcohol is a diuretic that suppresses antidiuretic hormone (ADH) secretion, increasing free water excretion and potentially reducing effective circulating volume [10]. Reduced circulating volume directly worsens contrast nephropathy risk by decreasing renal perfusion pressure. Patients scheduled for contrast imaging should avoid alcohol for at least 24 hours before the procedure, independent of their MOTS-c status.

Alcohol and MOTS-c Metabolic Effects

MOTS-c enhances insulin sensitivity and modifies glucose homeostasis through AMPK [1]. Alcohol consumption acutely inhibits gluconeogenesis and can compound hypoglycemia in people using insulin sensitizers [10]. While MOTS-c is not a direct insulin secretagogue, the combined metabolic perturbation of alcohol plus MOTS-c in a fasted, pre-procedure patient warrants caution. Hold alcohol 24 hours before any planned procedure requiring contrast.

What to Tell Your Radiology Team

Radiology staff completing pre-contrast screening questionnaires need complete medication lists, and off-label peptides are commonly omitted. The ACR recommends that contrast decisions include a review of "all medications that affect renal blood flow or tubular function" [4]. MOTS-c's AMPK-mediated effects on tubular cells arguably place it in that category.

Information to Provide

Tell the radiologist or technologist:

• The name "MOTS-c mitochondrial peptide"
• Your typical dose (e.g., 5 mg or 10 mg subcutaneous)
• Frequency of dosing (daily, three times weekly, etc.)
• Date and time of your most recent injection
• Your most recent eGFR value and the date it was drawn

Pre-Scan Lab Checklist

Patients using MOTS-c who are scheduled for contrast-enhanced imaging should confirm the following before arriving:

• Serum creatinine and eGFR drawn within 30 days
• Complete medication list reviewed by the ordering physician
• Hydration plan confirmed (oral or IV) with the radiology team
• Alcohol avoided for 24 hours prior

Known Drug Interactions with Imaging Contrast: Context for MOTS-c Users

Understanding how established drugs interact with contrast agents gives context for MOTS-c's theoretical risks.

NSAIDs and Contrast

Nonsteroidal anti-inflammatory drugs (NSAIDs) reduce renal prostaglandin synthesis, impairing the compensatory vasodilation that protects the kidney during contrast osmotic load [11]. MOTS-c does not appear to inhibit prostaglandin pathways, making this a less relevant parallel.

Nephrotoxic Antibiotics

Aminoglycosides such as gentamicin are directly nephrotoxic and substantially increase CI-AKI risk when combined with iodinated contrast [11]. This interaction is well documented. If a MOTS-c user is also taking an aminoglycoside, the risk calculation shifts significantly and a non-contrast protocol should be strongly considered.

Diuretics

Loop diuretics taken before contrast imaging can cause volume depletion and worsen renal perfusion, increasing CI-AKI risk [11]. Patients combining MOTS-c with a loop diuretic (furosemide, bumetanide) should flag both drugs to their radiologist.

Current Research Gaps and What to Watch

The published literature on MOTS-c in humans remains sparse. A 2021 clinical trial (NCT04219748) registered on ClinicalTrials.gov examined MOTS-c in older adults with insulin resistance but did not evaluate renal outcomes or contrast interactions [3]. No imaging-specific trial exists.

What the Research Community Is Studying

Investigations published in Aging have focused on MOTS-c's effects on skeletal muscle, metabolic inflammation, and longevity pathways in rodents [3]. Renal pharmacology of MOTS-c in humans has not been a primary endpoint in any published RCT as of July 2025.

The Disclosure Imperative

The absence of evidence for an interaction is not evidence of absence of an interaction. The FDA's framework for drug interaction assessment, as outlined in its 2020 guidance document on in vitro drug interaction studies, requires systematic evaluation that has not yet been applied to MOTS-c [2]. Until that gap is filled, full disclosure to all treating clinicians remains the safest path.

Summary of Key Clinical Points

Patients using MOTS-c who need contrast-enhanced imaging face a situation with no direct trial data to guide the decision. The interaction concern is mechanistic, rooted in shared AMPK signaling and renal tubular effects, not pharmacokinetic in the classical sense. Check eGFR before any contrast scan. Disclose MOTS-c to the radiology team. Avoid alcohol for 24 hours before contrast procedures. If eGFR is <30 mL/min/1.73 m², escalate the conversation to a nephrologist before proceeding.